Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical biotech company that leverages AI for precision antibody development, but its lack of revenue and need for future funds increases risk. The company faces competition from more established firms with larger resources, and its patents may not fully protect its products. iBio is developing a bispecific antibody targeting TGF-β ligands for a potential treatment in disease progression of PH-HFpEF, but its products still have clinical and regulatory risks to be addressed.

Bears say

iBio is primarily a preclinical stage biotechnology company that is developing precision antibodies using AI-guided epitope-steering and monoclonal antibody optimization technology. While the company has shown promising results in preclinical studies with its products IBIO-600 and IBIO-610, it faces significant competition in the intensely competitive biotechnology and pharmaceutical industries. Additionally, the company is currently in a development stage, meaning it does not have any products generating revenue and will likely need to raise additional funds in the future, which could be challenging in the current financial environment. As a result, there is no guarantee that the company's products will ultimately receive market approval, and investors should be aware of the potential risks associated with investing in iBio.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.